CXCL9 and neoplasm: In summary, we have developed tumor-specific gene nanomedicines to specifically drive different tumor cells to coexpress CXCL9 and αPD-L1, which provide a solution for addressing both the lack of tumor-infiltrating T cells and the insufficient tumor enrichment of αPD-L1 inhibitors in ICB therapy.